Jun 15, 2020
Jazz Pharmaceuticals Announces U.S. FDA Accelerated Approval of Zepzelca(TM) (lurbinectedin) for the Treatment of Metastatic Small Cell Lung Cancer
Jun 09, 2020
Jazz Pharmaceuticals Announces Pricing of Private Offering of $850 Million of 2.000% Exchangeable Senior Notes due 2026
Jun 08, 2020
Jazz Pharmaceuticals Announces Private Offering of $850 Million of Exchangeable Senior Notes due 2026
May 27, 2020
Jazz Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences
May 14, 2020
Jazz Pharmaceuticals to Showcase New Data From its Growing Oncology Portfolio at Virtual ASCO and EHA 2020 Meetings
May 06, 2020
Jazz Pharmaceuticals Announces Participation at Upcoming Virtual Investor Conferences
May 05, 2020
Jazz Pharmaceuticals Announces First Quarter 2020 Financial Results
Apr 29, 2020
Jazz Pharmaceuticals Stops Enrollment in Phase 3 Study Evaluating Defibrotide for the Prevention of Veno-Occlusive Disease
Apr 21, 2020
Jazz Pharmaceuticals to Report 2020 First Quarter Financial Results on May 5, 2020
Mar 31, 2020
Jazz Pharmaceuticals Provides COVID-19 Business Update
Mar 25, 2020
Jazz Pharmaceuticals Announces FDA Acceptance of New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy
Feb 26, 2020
Jazz Pharmaceuticals Announces Participation at Upcoming Investor Conferences
Feb 25, 2020
Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2019 Financial Results
Feb 17, 2020
PharmaMar and Jazz Pharmaceuticals Announce FDA Acceptance and Priority Review of New Drug Application for Lurbinectedin in Relapsed Small Cell Lung Cancer
Feb 11, 2020
Jazz Pharmaceuticals to Report 2019 Fourth Quarter and Full Year Financial Results on February 25, 2020
Jan 22, 2020
Jazz Pharmaceuticals Submits New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy
Jan 22, 2020
PharmaMar and Jazz Pharmaceuticals Announce the U.S. License Agreement for Lurbinectedin is Effective with the Expiration of the HSR Waiting Period
Jan 06, 2020
Jazz Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference
Dec 19, 2019
PharmaMar and Jazz Pharmaceuticals Sign Exclusive License Agreement for Lurbinectedin in the U.S.
Nov 15, 2019
Jazz Pharmaceuticals Receives Positive CHMP Opinion for Solriamfetol to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea